Company / Cash per Share
BioXcel Therapeutics, Inc. Cash per Share History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash per Share
$9.16
FY2025
5-year range
$2.32 / $15.96
FY2022-FY2025
Trend
-42.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $2.32 to $9.16 over the past 2 years.
Based on SEC 10-K filings.
9.16 in FY2025 with a 3-year CAGR of +9.8%.
Improved from $2.32 to $9.16 over the past 2 years.
Cash per Share over time
Growth rates
- 3-Year CAGR
- +9.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, cash per share decreased 42.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -17.49 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.16 | -42.6% |
| FY2024 | $15.96 | +588.6% |
| FY2023 | $2.32 | -66.5% |
| FY2022 | $6.92 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026